Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Receivables: 2019-2022

Historic Change in Receivables for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2022 value amounting to -$47,000.

  • 4D Molecular Therapeutics' Change in Receivables rose 90.98% to -$47,000 in Q1 2022 from the same period last year, while for Mar 2022 it was -$965,000, marking a year-over-year decrease of 1222.09%. This contributed to the annual value of -$47,000 for FY2022, which is 96.73% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Change in Receivables of -$47,000 as of FY2022, which was up 96.73% from -$1.4 million recorded in FY2021.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Receivables registered a high of $508,000 during FY2020, and its lowest value of -$1.4 million during FY2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Change in Receivables value was -$47,000 (recorded in 2022), while the average stood at -$326,000.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Change in Receivables soared by 447.95% in 2020, and later crashed by 383.27% in 2021.
  • Yearly analysis of 4 years shows 4D Molecular Therapeutics' Change in Receivables stood at -$146,000 in 2019, then skyrocketed by 447.95% to $508,000 in 2020, then plummeted by 383.27% to -$1.4 million in 2021, then spiked by 96.73% to -$47,000 in 2022.